Rexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117

Jul 10, 2017

Rexahn Announces $10 Million Registered Direct Offering

Jun 7, 2017

Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

Jun 4, 2017

Rexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

May 8, 2017

Rexahn Effects 1-for-10 Reverse Stock Split

May 5, 2017

Rexahn Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update

May 4, 2017

Rexahn Announces 1-for-10 Reverse Stock Split

Apr 13, 2017

Rexahn Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Corporate Update

Feb 27, 2017

Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Trial of Supinoxin™ in Patients with Metastatic Triple Negative Breast Cancer

Feb 23, 2017

Rexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium

Jan 20, 2017